Celldex Therapeutics
CLDX | NASDAQ
$28.59
-$0.24 (-0.83%)
At close: Nov 16, 2026, 4:00 PM ET
$29.00
+$0.41 (+1.43%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Celldex Therapeutics Company Profile
Company profile explainedCompany Profile
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Anthony S. Marucci | Founder, President, Chief Executive Officer & Director |
| Sam Martin | Senior Vice President, Chief Financial Officer, Secretary & Treasurer |
| Diane C. Young | Senior Vice President & Chief Medical Officer |
| Elizabeth Crowley | Chief Product Development Officer & Senior Vice President |
| Freddy A. Jimenez | Senior Vice President & General Counsel |
| Joseph Schlessinger | Co-Founder & Member of Scientific Advisory Board |
| Margo Heath-Chiozzi | Senior Vice President of Regulatory Affairs |
| Ronald A. Pepin | Chief Business Officer & Senior Vice President |
| Sarah Cavanaugh | Senior Vice President of Corporate Affairs & Administration |
| Tibor Keler | Founder, Chief Scientific Officer & Executive Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 22, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 15, 2026 | 8-K | Current Report |
| Jun 29, 2026 | 4 | Filing |
| Jun 29, 2026 | 4 | Filing |
| Jun 29, 2026 | 4 | Filing |
Celldex Therapeutics
| Country | United States |
| IPO Date | May 15, 1986 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 198 |
| CEO | Anthony S. Marucci |
Contact Details
Perryville III Building Hampton,
New Jersey 08827 United States
Stock Details
| Ticker Symbol | CLDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000744218 |
| CUSIP Number | 15117B202 |
| ISIN Number | US15117B2025 |
| SIC Code | 2835 |
Recent News
- 7 days ago / marketbeat.comCelldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results
- 2 months ago / seekingalpha.comCelldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
- 2 months ago / benzinga.comCelldex Prepares For 2027 FDA Submission for Chronic Skin Disease
- 2 months ago / zacks.com4 Biotech Stocks With Key Clinical Readouts Expected This Fall
- 2 months ago / reuters.comCelldex's skin disease drug meets goals in two late-stage trials
- 2 months ago / globenewswire.comCelldex to Present at Upcoming Investor Conference
- 3 months ago / zacks.comCelldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
- 4 months ago / zacks.comAre Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
- 4 months ago / seekingalpha.comCelldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript
- 4 months ago / benzinga.comCelldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
Add to Watchlist
Select watchlists to add or remove CLDX